Membrane temperature offers clue to oral mucositis risk in head and neck cancer

Share this article:

Thermal imaging can detect small and early changes in the temperature of mucosal surfaces that may signal the development of mucositis in persons with head and neck cancer who are receiving chemotherapy and radiation therapy, according to the results of a pilot study. These mouth sores are a common, painful, and potentially very severe side effect of chemoradiotherapy for patients with this form of cancer, but perhaps could be avoided or minimized if clinicians could predict which patients were at greatest risk.

The pilot study involved 34 participants. All had locally advanced squamous cell carcinoma of the oral cavity or oropharynx, and all received baseline and weekly thermal imaging while undergoing identical chemoradiotherapy regimens. 

As lead author Ezra Cohen, MD, codirector of the head and neck cancer program at the University of Chicago, Chicago, Illinois, and colleagues reported at the Multidisciplinary Head and Neck Cancer Symposium, held January 26-28, 2012, in Phoenix, Arizona (, 53% of the participants developed grade 3 mucositis and 21% developed grade 3 dermatitis. All patients displayed an increase in temperature of oral mucous membranes within the radiation field.

The investigators observed a statistically significant positive association between an early rise in a reference area and mucositis grade. For every 1°C increase in temperature in the reference area, there was a 0.157 increase in average subsequent mucositis grade.

Cohen's team concluded that larger studies are needed to evaluate whether this tool can help predict which patients are in need of early intervention to prevent acute complications.

Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Web Exclusives

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.